Download PDF
Thromb Haemost 2013; 110(03): 393-395
DOI: 10.1160/TH13-07-0576
Invited Editorial Focus
Schattauer GmbH

Dabigatran monitoring made simple?

John W. Eikelboom
1   Department of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
,
Jeffrey I. Weitz
1   Department of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received: 18 July 2013

Accepted: 18 July 2013

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
    CrossrefPubMedSearch in Google Scholar
  • 2 Larsen TB, Rasmussen LH, Skjoth F. et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
    CrossrefPubMedSearch in Google Scholar
  • 3 You JJ, Singer DE, Howard PA. et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-e575S.
    CrossrefPubMedSearch in Google Scholar
  • 4 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
    CrossrefPubMedSearch in Google Scholar
  • 5 Skanes AC, Healey JS, Cairns JA. et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125-136.
    CrossrefPubMedSearch in Google Scholar
  • 6 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Pengo V, Cappa L, Falanga A. et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Lindahl TL, Baghaei F, Blixter IF. et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Douxfils J, Dogne JM, Mullier F. et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543-549.
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Harenberg J, Giese C, Marx S. et al. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38: 16-22.
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143.
    CrossrefPubMedSearch in Google Scholar
  • 14 Hapgood G, Butler J, Malan E. et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110: 308-315.
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Nehminz G, Ezekowitz MD, Reilly PA. et al. Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-1426.
    CrossrefPubMedSearch in Google Scholar
  • 16 Reilly PA, Lehr T, Haertter S. et al., on behalf of the RE-LY investigators The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients in the RE-LY Trial. J Am Coll Cardiol. 2013. in press
    Search in Google Scholar
  • 17 Harenberg J, Giese C, Marx S. et al. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38: 16-22.
    Thieme ConnectPubMedSearch in Google Scholar